Guggenheim Capital’s Summit Therapeutics SMMT Stock Holding History

Guggenheim Capital’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$988K	Buy	67,835 +1,433	+2%	+$25.4K	0.01%	1025
2026 Q1	$1.26M	Buy	66,402 +16,604	+33%	+$269K	0.01%	898
2025 Q4	$871K	Buy	49,798 +8,801	+21%	+$166K	0.01%	1011
2025 Q3	$847K	Buy	40,997 +6,538	+19%	+$159K	0.01%	976
2025 Q2	$733K	Sell	34,459 -6,198	-15%	-$141K	0.01%	1007
2025 Q1	$784K	Sell	40,657 -2,230	-5%	-$44.7K	0.01%	983
2024 Q4	$765K	Buy	+42,887	New	+$831K	0.01%	1033

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Guggenheim Capital's SMMT Position: Q2 2026 in Review

Guggenheim Capital increased its Summit Therapeutics (SMMT) stake by 2.2% in Q2 2026, buying an estimated $25.4K and bringing the position to 67,835 shares worth $988K. The position accounts for 0.01% of the portfolio, ranked #1025.

Guggenheim Capital first reported a position in SMMT in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.26M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Guggenheim Capital held 67,835 shares of Summit Therapeutics worth $988K as of Q2 2026.
Guggenheim Capital bought 1,433 Summit Therapeutics shares in Q2 2026, an estimated $25.4K.
Summit Therapeutics made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1025 holding.
Guggenheim Capital first reported a position in Summit Therapeutics in Q4 2024 and has held it in 7 quarters since.
Guggenheim Capital's Summit Therapeutics position peaked at $1.26M in Q1 2026.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.